全球医药产业研究与发展的必威体育精装版趋势PPT课件2.ppt

* * * * * * Platform tech deals including: bioassays, high throughput screening, genomics and combinatorial chemistry * * * Performance objectives must reflect importance Have people “on call” to evaluate opps Cross functional PRIDE at Novartis to do this * * * * * * * Key message Major companies (those with annual RD budgets exceeding US$1bn) tend to allocate a larger proportion of their RD budget towards the development of line extensions compared with smaller companies. A substantial shift in the focus of investment away from new active substances towards line extensions is evident however within both groups. Methodology 5 major companies and 6 other companies provided information on the proportion of their RD expenditure allocated to line extensions in 1997, 1999 and 2001. The average proportion of RD expenditure allocated to line extensions by company is presented. Definitions RD expenditure: The total expenditure on all research and development activities relating to ethical pharmaceuticals. This includes salaries and all other personnel-related costs, costs related to consumable materials and supplies, and an appropriate share of overheads to cover administration, depreciation, space charges, rent, etc. The cost of RD conducted by means of grants or contracts to other companies or institutions, and proportional costs for joint ventures is included. This definition excludes capital RD expenditure. Line extension: Active substances that are already marketed but are being further developed for new indications, formulations, dosages, routes of administration, or novel drug delivery systems. Major companies: Companies for which 2001 RD expenditure on ethical (prescription only) pharmaceuticals was US$1bn or over. Other companies: Companies for which 2001 RD expenditure on ethical (prescription only) pharmaceuticals was under US$1bn. CMR International Performance Metrics Programme / Source Pharmaceutical Investment and Output Survey / van den Haak, MA, Vounat